Longer-term analysis confirms the clinical benefit of neoadjuvant Nidlegy™ in locally advanced, fully resectable melanoma The publication represents an update of the PIVOTAL Phase III results previously published in Annals...
Read moreSiena, Italy, 27 July 2026 – Philogen S.p.A. (BIT:PHIL) is pleased to announce the submission of an updated Marketing Authorization Application (MAA) to the European Medicines Agency (EMA) for the...
Read more